Catamaran Bio
ClosedBoston, United States · Founded 2020 · $42.0M raised
- Headquarters
- Boston, Massachusetts
- Employees
- 11–50
- Founded
- 2020
- Business Model
- B2B
- Website
- catamaranbio.com
- Total Funding
- $42.0M
- Last Round
- $42.0M Series ANov 2020
- Rounds
- 1
About
Catamaran Bio was a Cambridge/Boston-based biotechnology company developing allogeneic, off-the-shelf CAR-NK cell therapies for the treatment of solid tumors and other cancers. Founded in 2020 by scientific pioneers in NK cell biology, the company built its proprietary TAILWIND platform — an integrated suite of technologies to engineer, expand, and process NK cells into potent, cryopreserved cell therapy products. Catamaran raised 42M USD in a Series A in November 2020 but wound down operations in January 2024.
Summary
Catamaran Bio is a Biotech company based in Boston, United States, founded in 2020. It has raised $42.0M in total across 1 round, most recently a $42.0M Series A round in Nov 2020. Investors include SV Health Investors, Sofinnova Partners and Lightstone Ventures.
Tech & App Stack
7 technologies & apps tracked
Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.
Funding History
Nov 2020
Investors
Similar Companies
China's leading blood products manufacturer
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biopharmaceutical services company
Specialty pharmaceutical company
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/catamaran-bio"><img src="https://indexed.vc/api/badge/company/catamaran-bio" alt="Catamaran Bio on Indexed.vc" width="260" height="76" /></a>